00 rpm in an SW28 rotor, re-suspended in 100 μl of .1% BSA in PBS and stored at -80°C.
MC-CPA or pLL3.7 (empty vector), the VSV-G envelope-encoding plasmid pMD.G, and the packaging plasmid CMVΔR8.74 (S13) using the calcium phosphate method. The supernatants were harvested 48 and 72 h post-transfection, pooled, passed through a 0.45 μm filter, ultracentrifuged for 2 h 20 min at 19,2 0 Lentiviral infection and characterization of CPA shRNA-containing mast cells.
2-5 week old BMCMCs were infected with virus carrying the CPA-targeting shRNA or the empty vector. Since pLL3.7 carries a CMV-GFP cassette, BMCMCs were sorted for GFP expression at 72-96 h after infection using FACS Aria (Becton Dickinson) and then were cultured in IMDM + 10 ng/ml IL-3 (Peprotech) + 10 ng/mL SCF (a gift from Amgen Inc.). Methoxyphenylazoformyl]-Phe-OH) specific for CPA. We also counted the numbers of mast cells in the peritoneum (as assessed by counting toluidine blue-positive PMCs in an improved
Neubauer chamber), and evaluated the appearance of mast cells in the mesentery. The latter point is important, since the migration of adoptively-transferred mast cells into the mesentery appears to be required for such mast cells to be able to provide protective function in a model of innate immunity to bacterial infection (S14). Mesenteric windows were prepared and stained with Csaba stain for mast cell detection (S6) . We also evaluated levels of mMCP-5 in
Western blots of CPA shRNA PMCs, which revealed that levels of mMCP-5 protein are
Assessment of peritoneal mast cell degranulation.
Cytospins were prepared from cells collected by peritoneal lavage, stained with MayGrünwald-Giemsa stain and examined under a light microscope at x 1,000 magnification to quantify the extent of peritoneal MC (PMC) degranulation. The slides were coded so that the observers assessing the extent of PMC degranulation were not aware of the identity of the individual slides. MC degranulation is expressed as the % of the PMCs examined (at least 60
PMCs per cytospin) in which >50% ("Extensive" degranulation of that cell), 10-50%
("Moderate" degranulation of that cell) or <10% ("None", indicative of no significant greatly reduced in such cells, a finding which has also been reported in mast cells derived SA (Biomedica, Vienna). All measurements of amounts of sarafotoxins or T-1 in peritoneal fluid were made at 60 min after injection or at the time of death, if that ooner.
contortrix contortrix venoms were urchased from Natural Toxins Research Center (Kingsville, TX); Apis mellifera venom was . from CPA-deficient mice (S15).
Sarafotoxin and ET-1 measurements.
Sarafotoxin concentrations were measured using an endothelin EIA with 100% crossreactivity for sarafotoxins (Cayman Chemical, Ann Arbor, MI), and ET-1 levels were measured by ELI E occurred s
Venoms.
Venom from Atractaspis engaddensis, obtained as described (S16) at are dry estimated at ~ 50% (S20). The ount of venom injected by a snake of a particular species can also vary according to the age e morphological eviden size or distribution of the granules (S11, 17, 18) .
Statistical analysis.
The differences in percentages of mice exhibiting death by 24 h after injection with S6b or various venoms was compared by Fisher's exact test, whereas analysis of variance (ANOVA)
for repeated measures was used to assess differences in body temperature responses. Unless otherwise specified, all other data were tested for st tw Chi-square tes data are presented as mean ± s.e.m. or mean + s.e.m.
Text Notes

1.
Currently, ~ 2.5 million people are bitten by poisonous snakes annually worldwide, and it has been estimated that ~ 50,000 to 125,000 individuals die each year as a result of snake bites; most of these deaths occur in the developing world (S19, 20) . However, not all snake bites result in the injection of the maximum potential amount of that snake's venom and some bites are actually "dry", in that the fangs penetrate the skin but, based on clinical observations and other types of assessment, little or no venom is injected (S21, 22) .
Depending on the species of venomous snake, <10% to as many as 80% of the bites can be hypothesis apparently remains to be tested. However, based on our findings with mouse mast cells, it is intriguing to speculate that ascidian test cells might be able to contribute to host defense at least in part by enhancing resistance to exogenous toxins present in the aquatic environment, whether these toxins are derived from microorganisms or other sources.
Our study focused on the role of mast cells in innate responses to venoms. However, it is well known that components of animal venoms can induce mammals to develop acquired immune responses to these substances, and that some individuals sensitized to venom components can develop anaphylaxis (S40, 41, 42, 43) . In humans and other mammals, anaphylaxis occurs when certain individuals previously sensitized to a particular antigen are exposed to even very small amounts of that antigen; this rapidly triggers the extensive local and systemic antibody-and antigen-dependent activation of mast cells and certain other effector cells, which then secrete large amounts of biologically-active mediators that result in severe and sometimes fatal pathophysiological responses in the unfortunate victim (S44, 45, 46, 47) . Mast cell activation is rapidly induced in this setting (within minutes of antigen exposure) because the mast cells in such sensitized subjects already have bo e invertebrates, also can induce mammals to surface FcεRI receptors, IgE antibodies which recognize the provoking antigens (S44, 45, 47) .
Because anaphylaxis can be triggered by quite small amounts of what often are intrinsically innocuous substances (such as components of peanuts or other foods), anaphylaxis is rightly regarded as the most grotesque example of a maladaptive immune response.
However, in addition to certain antigens which are otherwise harmless, substances in the venoms of stinging insects, including the honeybee, represent common inducers of anaphylaxis in humans (S48) . Components of the venoms of animals other than insects, including reptiles and terrestrial and marin develop anaphylactic reactivity (S41, 42, 43) . Indeed, the first scientific description of anaphylaxis reported the occurrence of this phenomenon in dogs that had been immunized with and then were re-exposed to preparations of the venomous marine organism, Physalia physalis (the Portuguese man-of-war) (S49).
If we are correct in our hypothesis that enhancing innate resistance to the toxicity of certain venoms and other toxins represents a phylogenetically ancient mast cell function, that developed before the evolution of acquired immunity in vertebrates (S50, 51), then we might also speculate that anaphylaxis represents the most extreme and maladaptive end of a spectrum of acquired immunological responsiveness to venom components that includes responses that can enhance resistance to venom toxicity. Specifically, it will be of interest to assess whether, in some settings, the ability of mast cells to bind to their surface antibodies that recognize venom components, a process that primes these mast cells to undergo especially rapid and extensive activation upon subsequent exposure to that venom, actually can enhance host defense against the toxicity of such venoms compared to that observed in animals exposed to that venom for the first time. By contrast, in other circumstances, perhaps because of factors in individual subjects or species that can enhance the intensity of such acquired immune responses or diminish the effects of those elements which limit their extent, failure to reduce levels of ET-1 in the peritoneal cavity (measured at time of death or at 60 min, whichever was sooner), and death (D and E), without influencing the extent of PMC degranulation induced by ET-1 (F). Although the effects were much less dramatic than those observed in PCI pretreated mice, chymostatin (150 μg in 300 μl of saline) pre-treated mice injected i.p. with either S6b (Fig. 1E) or ET-1 (D) also exhibited significant hypothermia compared to values in the corresponding vehicle-treated (saline, 300 μl) mice; however, all of the chymostatin (or vehicle) pretreated mice injected with S6b or A.e.v. appeared to recover fully and survive. By contrast, no significant differences were observed in the body temperature responses of mMCP-4-/-versus WT mice to either S6b (Fig. S6A ) or ET-1 (A) (ANOVA). We suspect that the in vivo effects of chymostatin may well reflect the ability of this compound to diminish CPA activity. Indeed, we find that chymostatin can reduce the activity of CPA by up to 40% in vitro (G), as assessed by comparing the effects of vehicle (Veh), chymostatin (Chy, 120 μg) or potato carboxypeptidase inhibitor (PCI, 150 μg) added to lysates from 3 x 10 6 C57BL/6 peritoneal cells containing 1 x 10 5 peritoneal MCs at 37 o C (total volume 150 μl) to change the absorbance of a chromogenic substrate specific for CPA (S3) . PCI, and to a much lesser albeit significant extent chymostatin, also prevented in part the degradation of ET-1 in vitro (H). ET-1 (1 nmol in 250 μl) was incubated ex vivo at 37 o C for 30 min with vehicle alone (DMEM), or with vehicle containing peritoneal lavage cells (PLCs) from C57BL/6 mice (1 x 10 6 total cells, containing 2 x 10 4 PMCs) which were co-incubated with vehicle alone, chymostatin (100 μM) or PCI (400 μg/ml). 
